Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 23 Next »


ACRINAmerican College of Radiology Imaging Network
I-SPY TRIALInvestigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis
CALGBCancer and Leukemia Group B
TCIAThe Cancer Imaging Archive
NACTNeoadjuvant chemotherapy
SERSignal Enhancement Ratio
FCMFunctional Tumor Volume



ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting response and survivalAdd protocol references for all three studies.
Participant Eligibility and Enrollment: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an  anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.

Requirements for MR imaging (As specified in the ACRIN 6657 protocol )

Imaging time points: MRI exams were performed within four weeks prior to starting anthracycline-cyclophosphamide chemotherapy (T1, MRI1), at least 2 weeks after the first cycle of AC and prior to the second cycle of AC (T2, MRI2), between anthracycline-cyclophosphamide treatment and taxane therapy if taxane was administered (T3, MRI3), and after the final chemotherapy treatment and prior to surgery (T4, MRI4). The study schema is shown in Figure 1

Figure 1. I-SPY 1 TRIAL and ACRIN 6657 study schema.

Imaging protocol: MR imaging was performed on a 1.5 Tesla field strength scanner using a dedicated breast radiofrequency coil. The image acquisition protocol included a localization scan and T2-weighted sequence followed by a contrast-enhanced T1-weighted series. All imaging was performed unilaterally over the symptomatic breast and in the sagittal orientation. The contrast-enhanced series consisted of a high resolution (≤1mm in-plane spatial resolution) three-dimensional, fat-suppressed, T1-weighted gradient echo sequence with TR≤20 ms, TE = 4.5 ms, flip angle ≤ 45º, 16-18 cm field-of-view, minimum matrix 256x192, 64 slices, slice thickness ≤ 2.5 mm. Scan time length for the T1-weighted sequence was required to be between 4.5 and 5 minutes. The sequence was acquired once before contrast injection and repeated at least twice following injection.
Tumor diameter measurement and volumetric analysis: Tumor longest diameter (LD) was measured by the site radiologist as the greatest extent of disease on baseline MR images, including intervening areas of non-enhancing tissue. The same measurement direction was used on all subsequent MRI exams. The primary predictor variable, functional tumor volume (FTV) was measured from contrast-enhanced images using the signal enhancement ratio (SER) method. Voluetric analysis, including Quality Control assessment, was performed centrally at the breast MR imaging laboratory at University of California at San Francisco (UCSF).

Further information can be found at:

Data Access

This is a limited access data set. To request access, please contact (ACRIN Contact). If access is granted you will be able to view and download these images on The Cancer Imaging Archive (TCIA) by logging in and selecting the I-SPY1 collection. This data set will be made publicly available on or before XXXX XX, 20XX.

Imaging Data

Collection Statistics

(updated 6/18/2015)



Number of Patients


Number of Studies


Number of Series


Number of Images


Images Size (GB)76.2 GigaBytes


This shared data set was provided by the Breast Imaging Research Program at UCSF, in collaboration with ACRIN, the I-SPY TRIAL, and TCIA.

David Newitt, PhD, UCSF, Nola Hylton, PhD, UCSF  

Funding sources include:

UCSFR01 CA132870 and U01 CA151235
ACRINCA079778 and CA080098
I-SPYCA31964 and CA33601

((( Insert full acknowledgement lists here )))


ISPY 1 - Collection Description

If you are unsure how to download this Collection please view Searching by Collection or refer to The Cancer Imaging Archive User's Guide for more detailed instructions on using the site.

Imaging Data Transfer Process

The processing of the MR image data for ACRIN 6657 / I-SPY 1 consisted of the following steps between image acquisition and the creation of this shared data set on TCIA:

  • MRI studies were sent from the study centers to ACRIN Core Lab either via media (DVD) or the TRIAD program
  • Image data were de-identified and centrally archived at ACRIN Core Lab
  • Archived data was sent to the breast MR imaging laboratory at University of California at San Francisco (UCSF) for volumetric analysis.
  • De-identified image data, derived analysis maps and segmentations, and ancillary data files were transferred from UCSF to TCIA for data sharing.

While every effort was made to preserve the integrity of both the original image data and image meta-data (DICOM attributes, public and private), multiple file transfers and strict adherence to HIPPA guidelines for patient confidentiality may have resulted in loss of some data. If any questions arise, or patient PHI is found in any data on this collection, please contact David Newitt at the Breast Imaging Research Program, UCSF ( 

In addition to the complete set of ACRIN 6657 imaging studies, curated data sets based on UCSF QC assessment, protocol compliance and data completeness are provided for download in the form of TCIA shared lists. These image data sets are accompanied by Excel files with patient clinical and outcome data.

Shared Lists: See descriptions below under "Curated Data Sets"

Level 0: All I-SPY 1 Dataset

847 MR on-study studies (222 subjects) in UCSF image database.
One patient in the image data collection (I-SPY ID 1079 ) does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.

Level 1: LD Dataset

Studies with MRI measured longest diameter
839 MR studies have LD reported in the I-SPY 1 clinical database
834 MR studies (219 subjects) in UCSF image database with LD

5 studies that have LD measurement are missing from
the UCSF and ACRIN TRIAD image data collections:

1071, T1
1138, T1

1101, T3
1040, T4

1187, T4

Level 2a: Good SER Volume Dataset – updated 9/3/14

Level 2a consists of 708 MR studies (208 subjects) in the UCSF image database which, following quality review in 2014, were judged to have sufficiently good image quality and protocol compliance for volumetric DCE SER analysis. Rejection criteria included: incomplete volumetric DCE acquisitions, lack of a 2nd post-contrast acquisition, variability in fat suppression across the image, observed patient motion during the DCE acquisition

7 studies in Level 2a that do NOT have LD measures:

ID 1059, T4
ID 1079, T2 *
ID 1104, T4

ID 1192, T2
ID 1212, T4

ID 1215, T1
ID 1238, T2

  • Patient 1079 does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.

Level 2b: SER Volume Dataset submitted to ACRIN in 2008

This data set is not provided as a shared list, as it is not recommended for use in any analysis. It is described here because it is the data set from which the Level 3 (primary aim analysis) set was derived.

Level 2b consists of 707 MR studies (207 subjects) in the UCSF image database which were submitted to ACRIN at the close of the trial in 2008. Inclusion and exclusion was determined by quality and protocol reviews available at that time. In addition to the exclusion criteria listed for Level 2a, studies done with imaging in the axial plane, in violation of the sagittal orientation specified in the trial imaging protocol, were excluded due to processing limitations of the analysis software. Similarly, bi-lateral sagittal acquisitions (alternating left and right volumetric acquisitions) were excluded.

Specific inclusion/exclusion differences between Levels 2a and 2b:

15 studies accepted for SER analysis since 2008 (in Level 2a but not in 2b)

ID 1005, T3
ID 1043, T2
ID 1046, T4
ID 1057, T3
ID 1074, T3
ID 1084, T1

ID 1110, T4
ID 1139, T4
ID 1159, T4
ID 1176, T2
ID 1201, T2

ID 1203, T4
ID 1206, T4
ID 1225, T3
ID 1219, T3
ID 1228, T4

14 studies rejected since 2008 (in Level 2b but not in 2a)

ID 1035, T4 *
ID 1045, T1
ID 1047, T1 *
ID 1053, T2 *
ID 1053, T4 *

ID 1055, T1 *
ID 1086, T1 *
ID 1091, T1 *
ID 1095, T2 *
ID 1173, T3 *

ID 1206, T1
ID 1206, T2
+2 exams for ineligible patient:
ACRIN ID 128 (no I-SPY ID)

* Subjects that were included in the primary aim analysis (Level 3)

Level 3: Subset of Level 2b used in primary aim analysis

586 MR studies (162 subjects) in UCSF image database

45 subjects excluded from Level 2b set

ID 1027

ID 1040

ID 1045

ID 1046

ID 1048

ID 1054

ID 1063

ID 1067

ID 1079

ID 1084

ID 1103

ID 1110

ID 1120

ID 1137

ID 1139

ID 1152

ID 1157

ID 1159

ID 1160

ID 1167

ID 1171

ID 1176

ID 1177

ID 1180

ID 1182

ID 1185

ID 1187

ID 1189

ID 1192

ID 1194

ID 1203

ID 1206

ID 1210

ID 1212

ID 1214

ID 1215

ID 1219

ID 1221

ID 1222

ID 1228

ID 1234

ID 1235

ID 1237

ID 1238



Case  #: 128


Shared Lists For Curated Data Sets

The following links may be used to download the image series for each of the main curated data sets: Level 1, 2a, and 3. For each level one may download either:

"All Series"               full MRI datasets including all original series and derived PE, SER maps and segmentation objects from the primary analysis

"DCE + Derived"      Original DCE series and derived PE, SER maps and segmentation objects from the primary analysis

"DCE Only"              Original DCE series only

 N subjectsAll SeriesDCE + DerivedDCE OnlyClinical dataOutcome data
Level 1: Studies with MRI LD measurements219     
Level 2a: Studies with SER Volume measurements208     
Level 3: Studies used in primary aim analysis162 

PrimaryAim DCE+Derived



Data Dictionary

A data dictionary is provided. The dictionary includes descriptions of all private DICOM attributes used in the derived maps and segmentations generated by the volumetric analysis and QC evaluations. Also included are descriptions of ancillary data provided, including demographic, clinical and survival data.

  • No labels